Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinic Hepatic Metabolism and Nicotine Addiction
NCT03442413Phase 1Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jun 2018
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nicotine and 2'-[18F]Fluorofolic acid in Tobacco Use Disorder (TUD), sponsored by University of Pennsylvania. Primary endpoints: Brain nAChR availability affected by duration of abstinence at 2 years and Brain nAChR availability affected by nicotine administration at 2 years. Started Jun 2018; status: active, not recruiting.
02
Drugs
nicotine2'-[18F]Fluorofolic acid
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT03442413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03442413.